Share on Facebook Share on Twitter Email
Answers.com

thrombocytopenia

 
Medical Encyclopedia: Thrombocytopenia

Definition

Thrombocytopenia is an abnormal drop in the number of blood cells involved in forming blood clots. These cells are called platelets.

Description

Thrombocytopenia is a blood disease characterized by an abnormally low number of platelets in the bloodstream. The normal amount of platelets is usually between 150,000 and 450,000 cells per microliter of blood. A microliter is an amount equal to one one-millionth of a liter (a liter is almost equal to a quart). Platelet numbers are counted by having a blood sample collected and placing a measured amount of blood in a machine called a cell counter. When the platelet number drops below 150,000 cells per microliter of blood, this person is said to be thrombocytopenic.

— Dominic De Bellis, PhD



Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Dictionary: throm·bo·cy·to·pe·ni·a   (thrŏm'bə-sī'tə-pē'nē-ə) pronunciation
Top
n.
An abnormal decrease in the number of platelets in circulatory blood.

thrombocytopenic throm'bo·cy'to·pe'nic adj.

Oncology Encyclopedia: Thrombocytopenia
Top

Key Terms: Asymptomatic, Congenital, Gamma globulin, Microliter, Neonatal, Stent.

Description

Thrombocytopenia (thrombocythemia) is a blood disorder characterized by an abnormally low number of circulating platelets (thrombocytes) in the bloodstream. Because platelets play an important role in the process of coagulation (blood clotting) and in the plugging of damaged blood vessels, persons with decreased platelets bruise easily and can have episodes of excessive bleeding (hemorrhage). Thrombocytopenia is usually an acquired disorder, but it can also be congenital, as in neonatal rubella (German measles).

Platelets are irregular, disc-shaped fragments of large cells called megakaryocytes, which are found in the spongy center of long bones (bone marrow). They are the smallest cell-like structures in the blood. When a blood vessel is punctured or damaged, normal mature platelets have a tendency to aggregate (group) together at the site, forming a plug that stops the bleeding. The lifespan of platelets in the blood is relatively short (five to ten days), so the bone marrow of healthy individuals is continually producing new platelets to replace the old ones.

Doctors usually use a combination of the physical examination, the medical history, and laboratory testing to diagnose this disorder. The platelet count, which is part of a complete blood count (CBC), is a key diagnostic tool. It measures the number of platelets in a volume of blood. The blood normally contains between 150,000 and 400,000 platelets per microliter (cubic millimeter or mm3) of blood. (A million microliters is equal to one liter, or about 1.1 quarts.) In adults, a platelet count of less than 100,000/microliter is considered low, but might occur without symptoms. Abnormal bleeding often occurs when the platelet count is below 30,000/microliter. If the count falls below 10,000/microliter, abnormal external bleeding is usually evident, and serious internal bleeding can be life threatening.

Causes

Thrombocytopenia occurs when any of the following abnormal conditions exist:

  • decreased production of platelets by the bone marrow
  • increased destruction of circulating platelets
  • increased trapping of platelets by the spleen
  • platelet loss from hemorrhage

The most common cause of thrombocytopenia is a decrease in the production of platelets by the bone marrow. When abnormalities develop in the bone marrow, the megakaryocytes (platelet precursors) can lose their ability to produce platelets in sufficient amounts. This is a common side effect of blood cancers such as leukemia, which causes an abnormal growth of white blood cells in the bone marrow. These abnormal cells crowd out the normal bone marrow cells, including the platelets. Other diseases that cause this condition are tumors that spread (metasta-size) to the bone, aplastic anemia, and viral infections such as rubella. Radiation and drugs used in cancer chemotherapy and in the treatment of other serious diseases can also cause the bone marrow to malfunction in this way, especially if they are used together. Some drugs, such as aspirin or heparin, do not actually cause a decrease in the number of platelets, but they destroy the functional ability of the platelets to aggregate.

Platelets can break down in unusually high amounts in persons with abnormalities in their blood vessel walls, with blood clots, or with man-made replacement heart valves. Devices (stents) placed inside blood vessels to keep them from closing (because of weakened walls or fat build-up) can also cause an increased destruction of platelets. In addition, severe microbial infections, infection with the human immunodeficiency virus (HIV), the virus that causes AIDS, and other changes in the immune system can speed up the removal of platelets from the circulation.

Normally, the spleen holds about one-third of the body's platelets as part of this organ's function to recycle certain aging or damaged blood cells. When liver disease or cancer of the spleen is present, the spleen can become enlarged (a condition called splenomegaly) and trap many more platelets than normal. Because a greater number of platelets remain in the enlarged organ, fewer platelets are circulating in the bloodstream.

Treatments

Sometimes this disorder is asymptomatic and does not require any treatment. This is often the case when thrombocytopenia occurs in children following a viral infection. Even when the disorder is a side effect of both radiation therapy and chemotherapy, if the thrombocytopenia is not severe, it is often reversible on its own once the therapies end.

Treatments, when necessary, vary with the severity of the disorder, the abnormal condition that caused the disorder, and any underlying or secondary cause. When possible, the best form of treatment is to eliminate whatever is causing the condition. For example, if a drug is causing the thrombocytopenia, eliminating that drug would be the ideal solution. However, when the disorder is a side effect of chemotherapy, the patient might need to continue the drug therapy. In such cases, the doctor must decide whether it is in the best interest of the patient to continue with the same dosage, to lower the dosage, to try an alternative drug, or to give the patient a platelet transfusion. For diseases other than blood cancers, doctors can sometimes continue the chemotherapy at full dosage by also giving the patient a platelet growth factor called Oprelvekin (marketed as Neumega) to boost the production of normal platelets in the bone marrow.

If a dysfunctional immune system is destroying the patient's platelets, the doctor might use a corticosteroid (such as prednisone) or gamma globulin to suppress the patient's immune response and to help maintain adequate platelet levels. Corticosteroids can also have unwanted side effects, so doctors usually do not use this treatment for very long.

If an enlarged spleen is the underlying cause of the thrombocytopenia, the doctor might want to try corticosteroids or epinephrine to release platelets from the spleen. If these methods fail, surgical removal of the spleen (splenectomy) can help to raise the platelet level since the spleen is no longer there to capture the platelets. However, the disease that caused the enlarged spleen, such as lymphoma or cancer that spread to the spleen from another area of the body, should be treated as well.

If the patient is having severe external or internal bleeding as the result of injury or disease, a platelet transfusion might be necessary for immediate results. This is especially true if laboratory tests show a decreased production of platelets in the bone marrow.

Alternative and Complementary Therapies

A natural substance called thrombopoietin shows promise as a regulator of platelet production.

Many over-the-counter medicines, herbal supplements (such as garlic, ginger, feverfew, and ginko biloba) and vitamins can affect the ability of platelets to function properly. To determine the best treatment for a patient and to avoid drug interactions, the doctor needs to know every drug and remedy a patient is taking.

Resources

Books

Altman, Roberta, and Michael J. Sarg. The Cancer Dictionary, Rev. ed. New York: Checkmark Books, 2000.

Komaroff, Anthony L. Harvard Medical School Family Health Guide. New York: Simon & Schuster, 1999.

Periodicals

Henderson, C.W. "Study Results Suggest Hope for Previously Untreatable Patients." Blood Weekly 16 November 2000: 20.

Other

"Side Effect Management Series: Low Blood Platelets (Thrombocytopenia)." Oncology.com. 2001. [cited June 28, 2001]. .

—Beverly Miller, MT(ASCP); Dominic De Bellis

Wikipedia: Thrombocytopenia
Top
Thrombocytopeni
Classification and external resources
ICD-10 D69.6, P61.0
ICD-9 287.3, 287.4, 287.5
OMIM 188000 313900
DiseasesDB 27522
MedlinePlus 000586
MeSH D013921

Thrombocytopenia (or -paenia, or thrombopenia in short ) is the presence of relatively few platelets in blood.

Generally speaking, in humans, a normal platelet count ranges from 150,000 and 450,000 per mm3.[1] These limits, however, are determined by the 2.5th lower and upper percentile, and a deviation does not necessarily imply any form of disease. The number of platelets in a blood sample also decreases rather quickly with time and a low platelet count may be caused by a delay between sampling and analysis.

One common definition is a number lower than 100,000.[2][3]

Contents

Signs and symptoms

Often, low platelet levels do not lead to clinical problems; rather, they are picked up on a routine full blood count (or CBC, complete blood count). Occasionally, there may be bruising, particularly purpura in the forearms, nosebleeds and/or bleeding gums.

It is vital that a full medical history is elicited, to ensure the low platelet count is not due to a secondary process. It is also important to ensure that the other blood cell types red blood cells, and white blood cells, are not also suppressed.

Diagnosis

Laboratory tests might include: full blood count, liver enzymes, renal function, vitamin B12 levels, folic acid levels, erythrocyte sedimentation rate, and peripheral blood smear.

If the cause for the low platelet count remains unclear, bone marrow biopsy is often undertaken, to differentiate whether the low platelet count is due to decreased production or peripheral destruction.


Thrombocytopenia in hospitalized alcoholics may be caused by splenomegaly, folate deficiency, and, most frequently, a direct toxic effect of alcohol on production, survival time, and function of platelets. Platelet count begins to rise after 2 to 5 days' abstinence from alcohol. The condition is generally benign, and clinically significant hemorrhage is rare.

Causes

Decreased platelet counts can be due to a number of disease processes:

Decreased production

Increased destruction

Medication-induced

Thrombocytopenia-inducing medications include:

  • Direct myelosuppression
  • Immunological platelet destruction
    • Drug binds Fab portion of an antibody. The classic example of this mechanism is the quinidine group of drugs. The Fc portion of the antibody molecule is not involved in the binding process.
    • Drug binds to Fc, and drug-antibody complex binds and activates platelets. Heparin induced thrombocytopenia (HIT) is the classic example of this phenomenon. In HIT, the heparin-antibody-platelet factor 4 (PF4) complex binds to Fc receptors on the surface of the platelet. Since Fc portion of the antibody is bound to the platelets, they are not available to the Fc receptors of the reticulo-endothelial cells, so therefore this system cannot destroy platelets as usual. This may explain why severe thrombocytopenia is not a common feature of HIT.
    • Abciximab induced thrombocytopenia.

More extensive lists of thrombocytopenia-inducing medications are available.[6]

Treatment

Treatment is guided by etiology and disease severity. The main concept in treating thrombocytopenia is to eliminate the underlying problem, whether that means discontinuing suspected drugs that cause thrombocytopenia, or treating underlying sepsis. Diagnosis and treatment of serious thrombocytopenia is usually directed by a hematologist.

Specific treatment plans often depend on the underlying etiology of the thrombocytopenia.

Condition Treatment
Thrombotic thrombocytopenic purpura Treatment of thrombotic thrombocytopenic purpura is a medical emergency, since the hemolytic anemia and platelet activation can lead to renal failure and changes in the level of consciousness. Treatment of TTP was revolutionized in the 1980s with the application of plasmapheresis. According to the Furlan-Tsai hypothesis[7][8], this treatment theoretically works by removing antibodies directed against the von Willebrand factor cleaving protease, ADAMTS-13. The plasmapheresis procedure also adds active ADAMTS-13 protease proteins to the patient, restoring a more physiological state of von Willebrand factor multimers. Patients with persistent antibodies against ADAMTS-13 do not always manifest TTP, and these antibodies alone are not sufficient to explain the how plasmapheresis treats TTP.
Idiopathic thrombocytopenic purpura Many cases of ITP can be left untreated, and spontaneous remission (especially in children) is not uncommon. However, counts of under 50,000 are usually monitored with regular blood tests, and those with counts of under 10,000 are usually treated, as the risk of serious spontaneous bleeding is high with a platelet count this low. Any patient experiencing severe bleeding symptoms is also usually treated. The threshold for treating ITP has decreased since the 1990s, and hematologists recognize that patients rarely spontaneously bleed with platelet counts greater than 10,000—though there are documented exceptions to this observation.

Treatments for ITP include:

Thrombopoetin analogues have been tested extensively for the treatment of ITP. These agents had previously shown promise but had been found to stimulate antibodies against endogenous thrombopoeitin or lead to thrombosis.

Romiplostim (trade name Nplate, formerly AMG 531) was found to be safe and effective for the treatment of ITP in refractory patients, especially those who relapsed following splenectomy.[9][10][11]

Heparin-induced thrombocytopenia Discontinuation of heparin is critical in a case of HITT. Beyond that, however, clinicians generally treat to avoid a thrombosis, and patients started directly on warfarin after a diagnosis of HITT are at excess risk of venous limb gangrene. For this reason, patients are usually treated with a type of blood thinner called a direct thrombin inhibitor such as lepirudin or argatroban, which are approved by the U.S. Food and Drug Administration (FDA). Other blood thinners sometimes used in this setting that are not FDA-approved for treatment of HITT include bivalirudin and fondaparinux. Platelet transfusions are not a routine component of the treatment of HITT, since thrombosis, not bleeding, is the usual associated problem in this illness.
Congenital amegakaryocytic thrombocytopenia Bone Marrow/Stem Cell Transplant is the only thing that ultimately cures this genetic disease. Frequent platelet transfusions are required to keep the patient from bleeding to death until transplant is done, although this is not always the case.

Veterinary treatment

Thrombocytopenia caused by Feline Leukemia Virus and Feline immunodeficiency virus retroviral infections is treated with Lymphocyte T-Cell Immune Modulator.

References

  1. ^ "Platelet count aka thrombocyte count". Lab Tests Online UK. 2004-05-28. http://www.labtestsonline.org.uk/understanding/analytes/platelet/test.html. Retrieved 2008-05-22. 
  2. ^ Correia MC, Domingues AL, Lacerda HR, et al. (December 2008). "Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni". Trans. R. Soc. Trop. Med. Hyg.. doi:10.1016/j.trstmh.2008.11.017. PMID 19118853. http://linkinghub.elsevier.com/retrieve/pii/S0035-9203(08)00526-9. 
  3. ^ Cheung RC, McAuley RJ, Pollard JB (May 2005). "High mortality rate in patients with advanced liver disease independent of exposure to general anesthesia". J Clin Anesth 17 (3): 172–6. doi:10.1016/j.jclinane.2004.06.016. PMID 15896582. http://linkinghub.elsevier.com/retrieve/pii/S0952-8180(05)00051-6. 
  4. ^ Scaradavou A (March 2002). "HIV-related thrombocytopenia". Blood Rev. 16 (1): 73–6. doi:10.1054/blre.2001.0188. PMID 11914001. http://linkinghub.elsevier.com/retrieve/pii/S0268960X01901882. 
  5. ^ Watson, T. D (2006). "The Annals of Pharmacotherapy, Pantoprazole-Induced Thrombocytopenia". Annals of Pharmacotherapy 40: 758. doi:10.1345/aph.1G384. PMID 16569810. http://www.theannals.com/cgi/content/abstract/40/4/758. 
  6. ^ "moon.ouhsc.edu". http://moon.ouhsc.edu/jgeorge/drug%20ITP_single04.htm+. 
  7. ^ Furlan M, Lämmle B (2001). "Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease". Best Pract Res Clin Haematol 14 (2): 437–54. doi:10.1053/beha.2001.0142. PMID 11686108. 
  8. ^ Tsai H (2003). "Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura". J Am Soc Nephrol 14 (4): 1072–81. doi:10.1097/01.ASN.0000060805.04118.4C. PMID 12660343. 
  9. ^ Bussel J, Kuter D, George J, McMillan R, Aledort L, Conklin G, Lichtin A, Lyons R, Nieva J, Wasser J, Wiznitzer I, Kelly R, Chen C, Nichol J (2006). "AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP". N Engl J Med 355 (16): 1672–81. doi:10.1056/NEJMoa054626. PMID 17050891. 
  10. ^ AMGEN (2008-03-12). "Press release: Amgen Statement on Successful Outcome of Romiplostim Panel Meeting". Business Wire via drugs.com. http://www.drugs.com/nda/romiplostim_080313.html. Retrieved 2008-05-22. 
  11. ^ "US FDA panel backs Amgen's Nplate against ITP". Reuters. 2008-03-12. http://www.reuters.com/article/rbssHealthcareNews/idUSWAT00911720080312. Retrieved 2008-05-22. 

External links


 
 

 

Copyrights:

Medical Encyclopedia. © 2006 through a partnership of Answers Corporation. All rights reserved.  Read more
Dictionary. The American Heritage® Dictionary of the English Language, Fourth Edition Copyright © 2007, 2000 by Houghton Mifflin Company. Updated in 2009. Published by Houghton Mifflin Company. All rights reserved.  Read more
Oncology Encyclopedia. Gale Encyclopedia of Cancer. Copyright © 2006 by The Gale Group, Inc. All rights reserved.  Read more
Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Thrombocytopenia" Read more